Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.57 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.54 |
| ▸ | THRB | P10828 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.48 |
| ▸ | WNT3A | P56704 | 1/20 | 0.48 |
| ▸ | STS | P08842 | 2/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2252152 | 0.88 | GPR119 (0.60) | NAMPTGPR119THRBKDM4EMAPT | |
| SCHEMBL10243179 | 0.88 | NAMPT (0.58) | NAMPTGPR119THRBKDM4EMAPT | |
| SCHEMBL25273106 | 0.87 | NAMPT (0.57) | NAMPTGPR119THRBKDM4EMAPT | |
| SCHEMBL16447355 | 0.87 | NAMPT (0.57) | NAMPTGPR119THRBKDM4EMAPT | |
| SCHEMBL3529237 | 0.86 | NAMPT (0.56) | NAMPTGPR119THRBKDM4EMAPT | |
| SCHEMBL12440414 | 0.86 | NAMPT (0.56) | NAMPTGPR119THRBKDM4EMAPT | |
| SCHEMBL14790769 | 0.86 | NAMPT (0.56) | NAMPTGPR119THRBKDM4EMAPT | |
| SCHEMBL8310737 | 0.85 | NAMPT (0.60) | NAMPTGPR119THRBKDM4EMAPT | |
| SCHEMBL19160548 | 0.85 | NAMPT (0.55) | NAMPTGPR119THRBKDM4EMAPT | |
| SCHEMBL22638944 | 0.85 | NAMPT (0.55) | NAMPTGPR119THRBKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
| CN-1094035-A | Carboxylic acid derivative contains pharmaceutical composition of these compounds and preparation method thereof | THOMAE GMBH DR K (DE) | 1994-10-26 | — | — | CN | disclosed |
| EP-0604800-A1 | 4- 4- 4-(carboxyalkyl)-phenyl amino carbonyl -phenyl -piperedines as aggregation inhibitors | Dr. Karl Thomae GmbH (DE) | 1994-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | NAMPT 176/4885GPR119 708/4885THRB 4513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.